Format

Send to

Choose Destination
Arch Otolaryngol Head Neck Surg. 2011 Sep;137(9):930-4. doi: 10.1001/archoto.2011.154.

Postoperative clinical radiosensitivity in patients with fanconi anemia and head and neck squamous cell carcinoma.

Author information

1
Department of Otolaryngology-Head and Neck Surgery, New York Presbyterian Hospital, Weill Cornell Medical Center, NY 10021, USA.

Abstract

OBJECTIVE:

To describe the complications and adverse effects of postoperative radiotherapy in patients with Fanconi anemia (FA).

DESIGN:

Cohort study.

SETTING:

Patients with FA treated at community and tertiary care hospitals throughout the United States.

PATIENTS:

The study included patients with FA who were enrolled in the International FA Registry (IFAR) and who developed head and neck squamous cell carcinoma and received postoperative radiotherapy.

MAIN OUTCOME MEASURES:

Demographics of patients with FA and adverse effects and dosages of radiotherapy.

RESULTS:

Twelve patients with FA (7 men and 5 women) were identified. They developed cancers at a mean age of 35.5 years (age range, 20-48 years). The sites of primary cancer were the oral cavity (n = 8), larynx (n = 2), pharynx (n = 1), and unknown (n = 1). The median radiation dose was 5590 cGy (range, 2500-7020 cGy). The most common adverse effects were mucositis (n = 9), dysphagia (n = 8), and pancytopenia (n = 6). Other complications included esophageal stenosis, laryngeal edema, and wound breakdown. Radiotherapy could not be completed in 5 cases. Overall, 8 patients died, 4 during the course of radiotherapy. The postoperative disease-free survival time ranged from 0 to 55 months.

CONCLUSIONS:

Patients with FA have a high rate of complications from radiotherapy. Common adverse effects, particularly mucositis, are especially prevalent and difficult to manage in this population. Pancytopenia is common and may lead to further complications, particularly bleeding and infection. Overall survival is poor. Further study of the response to radiotherapy in patients with FA should be attempted to establish appropriate dosages to balance treating disease while limiting adverse effects.

PMID:
21930984
PMCID:
PMC3343719
DOI:
10.1001/archoto.2011.154
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center